ASRGL1 Antikörper

Produktnummer ABIN7865675

Dieser Maus Monoklonal Antikörper detektiert spezifisch ASRGL1 in IHC, WB und ELISA. Es zeigt Reaktivität gegenüber Proben von Human.

Kurzübersicht für ASRGL1 Antikörper (ABIN7865675)

Target: ASRGL1 (Isoaspartyl Peptidase/L-Asparaginase (ASRGL1))

Reaktivität: Human

Wirt: Maus

Klonalität: Monoklonal

Konjugat: Dieser ASRGL1 Antikörper ist unkonjugiert

Applikation: Immunohistochemistry (IHC), Western Blotting (WB), ELISA

Klon: 7B6

Produktdetails anti-ASRGL1 Antikörper

Verwendungszweck: anti-CRASH mouse monoclonal, 7B6, purified

Aufreinigung: affinity chromatography

Immunogen: with CRASH recombinant protein and synthetic peptide

Isotyp: IgG1 kappa

Anwendungsinformationen

Applikationshinweise:

IHC-paraffin_dilution: 1:50-1:100 (1-2 μg/mL, microwave treatment in 10 mM citrate buffer pH 6.0 recommended)

WB_dilution: 1:50-1:100 (1-2 μg/mL)

IHC-frozen_dilution: 1:50-1:100 (1-2 μg/mL)

elisa_dilution: assay dependent

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Liquid

Konzentration: 100 μg/mL

Buffer: PBS with 0.02 % sodium azide

Konservierungsmittel: Sodium azide

Vorsichtsmaßnahmen: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Lagerung: 4 °C

Informationen zur Lagerung: store at 2 - 8 °C

Details zu ASRGL1

Target: ASRGL1 (Isoaspartyl Peptidase/L-Asparaginase (ASRGL1))

Andere Bezeichnung: CRASH

Hintergrund: 7B6 reacts with CRASH, a 308 AA glycoprotein sharing 32 % homology with human asparaginase and identical to Asparaginase-Like Protein (ALP) found in rat sperm. CRASH is found in a variety of tumors but only occasionally in normal tissues. Especially ovarian cancers are highly positive. CRASH is further found in brain tumors, some colonic cancers, some lung cancers, some prostate cancers, uterine cancers, some breast cancers and some thyroid cancers. It was not found in serum. In Western blot 3 bands are demonstrated of 45 kDa, 28 kDa and 15 kDa. Positive control: Ovarian cancer, KM22 breast cancer cells.